Related Experiment Video
Updated: Aug 5, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
The ctDNA Paradigm: Dynamic Observation, Quantitative Analysis, and Interpretive Limits in Precision Oncology
Massimiliano Chetta1, Nenad Bukvic2, Alessandra Rosati3
1Complex Operative Unit of Pathological Anatomy and Molecular Diagnostics, San Giovanni di Dio Ruggi d'Aragona, Schola Medica Salernitana, Largo Città di Ippocrate, 84131 Salerno, Italy.
Genes
|July 28, 2026
Summary
Interpreting circulating tumor DNA (ctDNA) requires rigorous analysis to guide precision oncology. Understanding background noise from clonal hematopoiesis and variant allele frequency is crucial for accurate cancer detection.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Plasma ctDNA is a dynamic milieu, not just a passive tumor DNA reservoir.
- Interpreting ctDNA requires high analytical rigor for clinical application in precision oncology.
- Clonal hematopoiesis of indeterminate potential (CHIP) presents biological background noise, necessitating matched leukocyte sequencing.
Purpose of the Study:
- To review the interpretive rigor needed for translating ctDNA detection into actionable precision oncology.
- To critically re-evaluate assumptions about variant allele frequency (VAF) and its relationship to tumor burden.
- To explore advanced ctDNA analysis methods and reporting standards.
Main Methods:
- Re-evaluation of mathematical relationships between VAF, tumor fraction, copy-number, and mutation multiplicity.
- Examination of cancer cell fraction (CCF) estimation and clonal/subclonal event discrimination.
- Assessment of ultra-sensitive sequencing technologies, pre-analytical variables, fragmentomics, and methylation-based approaches.
Main Results:
- VAF does not always directly reflect tumor burden; CCF estimation is key.
- Reversion mutations indicate therapy-driven evolutionary adaptation.
- Fragmentomic and methylation data offer complementary signals, especially when mutational data is limited.
Conclusions:
- Accurate ctDNA interpretation demands accounting for CHIP and understanding VAF complexities.
- Advanced techniques like fragmentomics and longitudinal monitoring enhance diagnostic power.
- A systems-based framework integrating multi-omics data is essential for next-generation liquid biopsies in oncology.
